Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Exercise training and endothelial function in patients with type 2 diabetes: a meta-analysis
Qiu S, Cai X, Yin H, Sun Z, Zugel M, Steinacker JM, Schumann U
Cardiovascular Diabetology 2018 May 2;17(64):Epub
systematic review

BACKGROUND AND AIMS: Exercise training is considered a cornerstone in the management of type 2 diabetes, which is associated with impaired endothelial function. However, the association of exercise training with endothelial function in type 2 diabetes patients has not been fully understood. This meta-analysis aimed to investigate their associations with focus on exercise types. METHODS: Databases were searched up to January 2018 for studies evaluating the influences of exercise training with durations >= 8 weeks on endothelial function assessed by flow-mediated dilation (FMD) among type 2 diabetes patients or between type 2 diabetics and non-diabetics. Data were pooled using random-effects models to obtain the weighted mean differences (WMDs) and 95% confidence intervals (CIs). RESULTS: Sixteen databases were included. Exercise training resulted in an overall improvement in FMD by 1.77% (95% CI 0.94 to 2.59%) in type 2 diabetes patients. Specifically, both aerobic and combined aerobic and resistance exercise increased FMD by 1.21% (95% CI 0.23 to 2.19%) and 2.49% (95% CI 1.17 to 3.81%), respectively; but resistance exercise only showed a trend. High-intensity interval aerobic exercise did not significantly improve FMD over moderate-intensity continuous exercise. Notably, the improvement in FMD among type 2 diabetes patients was smaller compared with non-diabetics in response to exercise training (WMD -0.72%, 95% CI -1.36 to -0.08%) or specifically to aerobic exercise (WMD -0.65%, 95% CI -1.31 to 0.01%). CONCLUSIONS: Exercise training, in particular aerobic and combined exercise, improves endothelial function in type 2 diabetes patients, but such an improvement appears to be weakened compared with non-diabetics. TRIAL REGISTRATION: PROSPERO CRD42018087376.

Full text (sometimes free) may be available at these link(s):      help